Article Text

Download PDFPDF
Survival and causes of death in 366 Hungarian patients with systemic sclerosis
  1. L Czirják1,
  2. G Kumánovics1,
  3. C Varjú1,
  4. Z Nagy1,
  5. A Pákozdi2,
  6. Z Szekanecz2,
  7. G Szűcs2
  1. 1
    Department of Immunology and Rheumatology, Medical School, University of Pécs, Pécs, Hungary
  2. 2
    Third Department of Internal Medicine, Rheumatology Unit, Medical School University of Debrecen, Debrecen, Hungary
  1. Professor László Czirják, University of Pécs, Medical School, Department of Immunology and Rheumatology, H-7621 Pécs, Irgalmasok u. 1.; laszlo.czirjak{at}aok.pte.hu

Abstract

Objective: Survival analysis of a series of 366 consecutive patients with systemic sclerosis (SSc).

Methods: Clinical and laboratory data were evaluated from 1983 until 2005 using a standard protocol. The female/male ratio was 315/51. The mean (SD) age of the patients was 56.8 (12.2) years. The duration of disease was 12 (5–19) years with a median follow-up of 6 (3–12) years.

Results: Kaplan–Meier univariate analysis showed that renal, cardiac involvement, pigmentation disturbances, malabsorption, a forced vital capacity <50%, diffuse scleroderma, presence of early malignancy, anaemia, and increased erythrocyte sedimentation rate (ESR) were signs of unfavourable prognosis, whereas anti-centromere antibodies were indicators of a good survival. In the multivariate Cox proportional hazards model the presence of diffuse scleroderma, renal involvement, coexistence of a malignant disease, and increased ESR were poor independent prognostic signs. Elderly age at the onset of disease also caused an unfavourable outcome. A total of 86 SSc-related deaths were recorded during the follow-up. Of them, 65% were attributed to cardiorespiratory manifestation of disease. Tumour associated early death was found in 12 cases (14%).

Conclusions: In addition to the well-known factors influencing the outcome (diffuse subset, internal organ involvements, and inflammatory signs), the coexistence of scleroderma with a malignancy also causes a poor outcome.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: This work was supported by the Hungarian NKFP grant (1/026/2001), the Hungarian Ministry of Health and Social Welfare grant (ETT 643/2003), and by the National Foundation for Scientific Research grants (OTKA T26429, OTKA T043017).

  • Competing interests: None declared

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.